Polycystic Ovary Syndrome (PCOS) got a major rebrand this month on May 12, 2026.

Announced at the AE-PCOS Society meeting and published in The Lancet by Teede et al., this name change has taken the internet by storm!

We're officially transitioning from Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome (PMOS)--it's a mouthful (from nine syllables to fifteen!) but it's more accurate than PCOS.

This change has been debated in PCOS circles for over a decade--I've been part of a few conversations around this topic. Now, many people (from healthcare providers and scientists to patients and advocates) are looking at this change positively because it’s a much better representation of a multisystem condition that affects your whole body.

But as you can imagine, there’s also backlash and criticism. And rightfully so, especially since the fundamental reality of living with this condition hasn’t changed overnight.

Before we get into the healthcare politics of it all (the good, the bad, and the questionable) let’s answer the top four questions you’ve probably been frantically typing into Google. (I also have a podcast/YouTube episode all on this name change!)

What does PMOS stand for?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new, official medical term for what was previously known as PCOS (and before that, Stein-Leventhal Syndrome!).

Why was the name changed from PCOS to PMOS?

The name PCOS was reductive and misleading. It reduced a whole-body condition to the ovaries only.

You can have what we medically call polycystic ovarian morphology (PCOM), which are not even true cysts, but immature follicles that aren't growing properly, and not actually have the syndrome. Conversely, not everyone with the syndrome even has PCOM or polycystic ovaries!

The new name reflects the nature of the condition A LOT better:

• Polyendocrine: captures dysregulation in multiple hormones (like testosterone, SHBG, GnRH)
• Metabolic: pertains to insulin resistance, low-grade inflammation, central adiposity in some, and increased cardiometabolic risk
• Ovarian: addresses the anovulatory cycles, irregular cycles, polycystic ovaries, and ovarian hormone issues

The syndrome part, which refers to a cluster of signs and symptoms, remains unchanged.

Do I have to get re-diagnosed with PMOS if I already have PCOS?

Nope! PMOS is just an updated name for the exact same condition. Patients already diagnosed with PCOS automatically fall under the PMOS terminology. You’ll probably see it written with a caveat for a while, like PMOS (formerly PCOS) or PMOS (previously known as PCOS), or even PCOS/PMOS. I'll admit, it’s going to take me a bit of time to get accustomed to saying it, too! I've been saying PCOS for over a decade as someone who has PCOS/PMOS and as someone who treats A LOT of patients with the condition in Innisfil, Newmarket, and virtually across Ontario.

Does PMOS change my treatment plan?

At its core, no. Our fundamental understanding of the condition hasn't changed. That said, might you get slightly different (and, hopefully better (fingers crossed), care? Yes. Because we’ve put "metabolic" and "polyendocrine" right in the name, it stops providers from reducing your care entirely to ultrasounds and birth control. Hopefully lean PCOS/PMOS patients will get better care too.

PCOS to PMOS: the "why" and the global surveys

So, why go through all the trouble of changing a name that millions of people already know?

Now, let's get into this name change a bit deeper, especially looking at what was presented in The Lancet paper:

*Here is their exact, verbatim rationale for why this was necessary:

"Polycystic ovary syndrome affects more than 170 million women globally, yet its current name is inaccurate and misleading, obscuring the condition’s multisystem endocrine and metabolic features, reinforcing stigma, delaying diagnosis, and hindering effective clinical care, research, and policy alignment."*

Their rationale perfectly mirrors what patients have been saying for years: the old name obscured the condition’s metabolic features, reinforced stigma, delayed diagnosis, and hindered effective clinical care.

This change was born out of two massive global surveys and workshops (unfortunately and not surprisingly, populations in Asia, Africa, and South America where there's a high prevalence of PCOS/PMOS were under-represented in these surveys and workshops).

A few options were rejected because of what the acronym would sound like. "Metabolic Endocrine Reproductive Syndrome" was out because MERS is a severe respiratory disease. "Endocrine Metabolic Ovulatory Syndrome" (EMOS) was out because it overlapped way too closely with the "emo" youth subculture. So, they landed on PMOS, which conveniently only changes one letter.

Is it a perfect name? No. There is still pushback on keeping an ovarian term because it excludes people without ovaries and minimizes the fact that this is a lifelong issue well past menopause. But is it better than before? Yes.

The pros of the PCOS to PMOS name change

There are some very real upsides to this name change, like:

• A bright spotlight on PCOS/PMOS: It's bringing awareness and attention to the condition and it's multisystem nature. Hopefully, it instigates a renewed vigour for patient support, clinician learning, awareness, and funding.
• Ending the "polycystic ovaries" confusion: PCOS never actually referred to true ovarian cysts; they referred to altered folliculogenesis (immature follicles hanging out in arrested development). For decades, this confused both patients and health providers, leading to rampant misdiagnoses, especially in adolescents (polycystic ovaries can be commonly found in adolescence quite naturally as reproductive maturity has not been reached!). This is exactly why Anti-Müllerian Hormone (AMH) was added as a diagnostic marker in the 2023 guidelines--AMH is made by follicles in the ovaries, so more follicles = more AMH.
• The power of common language: Words have power. A shared language between patients, providers, and policymakers opens doors that weren’t open before, allowing us to utilize incredible therapeutics that fall in the metabolic health realm and not minimizing patient care to reproductive health alone.

The criticisms and cons of the PCOS to PMOS name change

Let’s talk about the very real criticisms and growing pains accompanying this change:

• Was it practically necessary? For those of us on the ground treating patients, we already knew it was metabolic and polyendocrine. A new name doesn't instantly fix a broken medical system that chronically dismisses, under-supports, and underdiagnoses patients.
• The SEO & Advocacy Cost: On a grassroots level, patient-led advocacy groups who have spent a decade building resources and training social media algorithms for "PCOS" may take a hit. Smaller groups will get the short end of the stick while well-funded institutions dominate the new search terms.
• The Social Science Backlash: Some critics complain that this name change from PCOS to PMOS funds and supports social science and economics instead of spending resources finding a "cure." But you can't separate a chronic disease from the human experiencing it. Ignoring the psychosocial toll, relationship strain, economic burden, and language confusion just perpetuates inadequate medical care. Not only that, this is a multifaceted LIFELONG condition with MANY contributing factors, so there isn't a singular "cure".
• Systemic Barriers: This is more of a general take. The science will get better and care will (hopefully!) improve. But we're watching political bait-and-switch tactics continually dismantle public protections and universal healthcare. Ultimately, your postal code and finances are playing a bigger role in your healthcare access than ever before, and I worry about the marginalized populations getting left behind as always.

PCOS to PMOS: the road ahead

It's gonna be a bumpy road--change comes with ups and downs (and twists and turns!).

The Lancet article lays out a specific 3-year implementation strategy. Expect to see integration into Electronic Health Records (EHR) and engagement with the World Health Organization to get this adopted into the ICD codes by the 2028 International Guidelines update.

I’ll be talking more about this topic in the fall once we’re on the other side of PMOS Awareness Month and we see how the industry adapts (especially keeping an eye on bad actors and profiteering with a change like this!).

Until then, we keep advocating, we keep questioning, and we keep the most important person in mind: YOU. Regardless of the acronym, the most important part of this whole conversation is your health and your care.

Make sure to send this to someone who would benefit from hearing it—a relative, a colleague, or your healthcare provider.

I have PMOS (formerly PCOS) and I treat a lot of patients with PCOS/PMOS in my practice in Innisfil, East Gwillimbury, and virtually across Ontario. If you're looking for a naturopathic doctor to support you, you can book an appointment here.

References & Resources: Teede et al., Lancet. May 2026. PMID: 42119588 AE-PCOS Society Phase to Phase: The Hormone Health Episode on PCOS to PMOS by Dr. Anne Hussain, ND